FLT3 and leukemia: Inhibition of autophagy enhanced the anti-leukemia effect of sorafenib in leukemia cell lines and primary blasts with FLT3-ITD + D835Y mutation, which opens a window for overcoming FLT3 inhibitor resistance in AML with acquired D835 mutation.